The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Open accessThe DOI matches its Crossref record; 119 of the 140 references it cites were found in a registry or an index; 9 of the 77 sources its claims cite were checked for support.
Abstract
OBJECTIVE: The objective of the study was to develop clinical practice guidelines for the diagnosis of Cushing's syndrome. PARTICIPANTS: The Task Force included a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, five additional experts, a methodologist, and a medical writer. The Task Force received no corporate funding or remuneration. CONSENSUS PROCESS: Consensus was guided by systematic reviews of evidence and discussions. The guidelines were reviewed and approved sequentially by The Endocrine Society's CGS and Clinical Affairs Core Committee, members responding to a web posting, and The Endocrine Society Council. At each stage the Task Force incorporated needed changes in response to written comments. CONCLUSIONS: After excluding exogenous glucocorticoid use, we recommend testing for Cushing's syndrome in patients with multiple and progressive features compatible with the syndrome, particularly those with a high discriminatory value, and patients with adrenal incidentaloma. We recommend initial use of one test with high diagnostic accuracy (urine cortisol, late night salivary cortisol, 1 mg overnight or 2 mg 48-h dexamethasone suppression test). We recommend that patients with an abnormal result see an endocrinologist and undergo a second test, either one of the above or, in some cases, a serum midnight cortisol or dexamethasone-CRH test. Patients with concordant abnormal results should undergo testing for the cause of Cushing's syndrome. Patients with concordant normal results should not undergo further evaluation. We recommend additional testing in patients with discordant results, normal responses suspected of cyclic hypercortisolism, or initially normal responses who accumulate additional features over time.
Overview
CoChat Summary
TL;DR
This Endocrine Society guideline recommends case detection for Cushing's syndrome only in selected high-risk groups, initial testing with one of four high-accuracy tests, and confirmatory second testing before cause-directed evaluation. It emphasizes excluding exogenous glucocorticoids first and notes that most recommendations rest on very low- to low-quality evidence.
Key findings
- Exclude exogenous glucocorticoid exposure before biochemical testing (1QQQQ); test patients with multiple and progressive features, unusual features for age, children with decreasing height percentile and increasing weight, or adrenal incidentaloma compatible with adenoma, and recommend against widespread testing in other groups.
- Initial testing should use one of: urine free cortisol (at least two measurements), late-night salivary cortisol (two measurements), 1-mg overnight dexamethasone suppression test, or 48-h 2 mg/d dexamethasone suppression test; recommend against random serum cortisol/plasma ACTH, urinary 17-ketosteroids, insulin tolerance test, loperamide test, and cause-directed tests for initial diagnosis.
- Reported test performance includes late-night salivary cortisol sensitivity 92–100% and specificity 93–100%; pediatric UFC sensitivity about 89%; 1-mg DST at a 1.8 µg/dL cutoff sensitivity >95% with specificity 80%, rising to >95% specificity at a 5 µg/dL threshold; LDDST sensitivity 96% and specificity 70%; dexamethasone-CRH sensitivity 98% and specificity 60%.
- Special-population recommendations: use UFC and avoid dexamethasone testing in pregnancy; avoid dexamethasone testing with enzyme-inducing antiepileptics; suggest 1-mg overnight DST rather than UFC in severe renal failure; suggest UFC or midnight salivary cortisol rather than DSTs in suspected cyclic Cushing's; suggest 1-mg DST or late-night cortisol rather than UFC in adrenal incidentaloma.
Methods
- A six-member Task Force appointed by The Endocrine Society's Clinical Guidelines Subcommittee, including a chair, five additional experts, a methodologist, and a medical writer, received no corporate funding or remuneration; consensus was guided by systematic reviews and discussions and approved sequentially by Society bodies and members.
- Recommendations used the GRADE approach: strong recommendations phrased “we recommend” with number 1, weak recommendations “we suggest” with number 2; evidence quality ranged from QEEE (very low) to QQQQ (high), informed by best available research evidence and systematic reviews/meta-analyses of test accuracy.
- The guideline presents evidence, values, and remarks linked to each recommendation; technical remarks often reflect the panel's unsystematic observations applied to a typical patient.
Limitations
- Stated: the majority of recommendations are based on very low- to low-quality evidence, with limited data linking diagnostic strategies to patient-important outcomes and no higher-quality direct evidence available.
- Stated: published data often come from larger tertiary referral centers and may be biased toward more diagnostically challenging cases, higher pretest probability, and greater disease severity, potentially giving an overly sanguine view of test performance in unselected populations.
- Evident from the text: this is a consensus guideline rather than a primary study, and some technical recommendations rest on unsystematic panel observations; data on treating mild/subclinical Cushing's syndrome and adrenal incidentaloma are described as limited and conflicting.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Valid · 4 Not valid · 37 Not checked · 33 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Another study of 86 consecutive obese subjects referred to an endocrine clinic with diabetes mellitus, hypertension, and/or the polycystic ovary syndrome found a 5.8% incidence of Cushing's syndrome (35).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.3 Evidence
What the sources say
- Partly supportedcites [35] 35. Ness-Abramof R, Nabriski D, Apovian CM, Niven M, Weiss E, Shapiro MS, Shenkman L 2002 Overnight dexamethasone suppression test: a reliable screen for Cushing's syndrome in the obese. Obes Res 10:1217-1221 sourceExperimental — accuracy not yet measured
The Patients section describes 86 obese patients referred to an endocrine clinic, and the Results report five Cushing’s syndrome diagnoses—5/86, or approximately 5.8%, though the paper prints 5.7%. The copy does not say the patients were consecutive. It also reports that 51 had obesity alone, so diabetes, hypertension, and polycystic ovary disease do not describe the whole group. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The salivary glands express 11-hydroxysteroid dehydrogenase type 2 (11-HSD2), which converts the biologically active cortisol to inactive cortisone (75).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Remarks for late-night salivary cortisol
What the sources say
- Supportedcites [75] 75. Smith RE, Maguire JA, Stein-Oakley AN, Sasano H, Takahashi K, Fuku- shima K, Krozowski ZS 1996 Localization of 11-hydroxysteroid dehydro- genase type II in human epithelial tissues. J Clin Endocrinol Metab 81:3244 - 3248 source
The paper reports 11β-HSD2 in the ducts of human parotid and submandibular salivary glands (Abstract; Discussion, p. 3247). It describes the enzyme as inactivating glucocorticoids and discusses salivary cortisol-to-cortisone ratios (Introduction; Discussion, p. 3247), supporting the stated function. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Overall, the evidence in adults suggests that the accuracy of this test is similar to that of UFC (2).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Evidence for late-night salivary cortisol
What the sources say
- Supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 source
Table 3 (Conclusions; page unavailable) reports broadly similar pooled diagnostic likelihood ratios for midnight salivary cortisol and UFC. The Summary of findings notes that evidence for salivary cortisol is more limited, consistent with the citing sentence’s cautious wording. (LLM, conf=0.88)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“When the assay upper limit of normal is used as a criterion, the overall evidence supports the diagnostic accuracy of UFC in adults suspected of having Cushing's syndrome (2,51).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.1 Evidence for use of UFC
What the sources say
- Partly supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 sourceExperimental — accuracy not yet measured
The Summary of findings says UFC has substantial evidence supporting its use to detect Cushing’s syndrome, and the pooled results table reports diagnostic accuracy across 14 UFC studies. The Subgroup analyses section identifies an assay-upper-limit cutoff, but the reported UFC estimate is pooled across studies rather than shown specifically for that cutoff. The Conclusions also limit the apparent accuracy to referral practices enriched with patients with Cushing’s syndrome; performance in usual clinical practice remains unclear. Page numbers were not available in our copy. (LLM, conf=0.83)
- Supportedcites [51] 51. Pecori Giraldi F, Ambrogio AG, De Martin M, Fatti LM, Scacchi M, Cav- agnini F 2007 Specificity of first-line tests for the diagnosis of Cushing's syndrome: assessment in a large series. J Clin Endocrinol Metab 92:4123- 4129 source
The UFC results (p. 2) report 91.2% specificity in Cushing’s syndrome suspects when values above the assay’s reference range were considered abnormal. The Discussion (p. 5) identifies that threshold as the assay’s upper limit of normal and describes UFC as having superior diagnostic performance. The study assessed specificity, rather than diagnostic accuracy across all measures. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The four recommended tests have acceptable diagnostic accuracy when the suggested cutoff points are used (2,30).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4 Evidence
What the sources say
- Partly supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 sourceExperimental — accuracy not yet measured
The Conclusions state that commonly used tests appear highly accurate in referral practices with samples enriched for Cushing’s syndrome, but that their performance in usual clinical practice is unclear. The Data extraction section says the review used cutoffs chosen by the primary studies, selecting those with the best performance when several were available; it does not establish accuracy specifically at the suggested cutoff points. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [30] 30. Batista DL, Riar J, Keil M, Stratakis CA 2007 Diagnostic tests for children who are referred for the investigation of Cushing syndrome. Pediatrics 120: e575-e586 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
48 more claims · 3 with their cited sources checked
Create a free account to see all 82 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 12
- It may state two separate claims as one. 20
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early diagnosis of secondary hypertension and the institution of appropriate targeted treatment have the potential to cure hypertension in some patients or improve BP control/reduce the number of prescribed antihypertensive medications in others.”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [118]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, accurate serum cortisol measurement is essential for the correct diagnosis and management of adrenal pathologies.”
From Serum cortisol: an up-to-date assessment of routine assay performance (2016) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the reliability of almost all markers of HPA axis activity, particularly ACTH and 24-h urinary free cortisol (UFC), is low (3,14,23)”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, UFC should not be considered an adequate screening test for SH and should be used in combination with other tests or in specific populations (1,14).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“some authors have proposed higher (3 or 8 mg) dexamethasone doses (40,46,54,56), which however did not show a better performance (14,23,66).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measured
27 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“biochemical hypercortisolism is present in a large fraction (up to 10%).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“Libe et al. (32) reported 18%; Terzolo et al. (21) quoted 5-20%, depending on referral bias and diagnostic tests and criteria.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > Subsequent evaluation
“3.9.1 We suggest the additional use of the dexamethasone-CRH test or the midnight serum cortisol test in specific situations (Fig. 1, 1QEEE).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > METHOD OF DEVELOPMENT OF EVIDENCE-BASED RECOMMENDATIONS
“strong recommendations use the phrase "we recommend" and the number 1, and weak recommendations use the phrase "we suggest" and the number 2.”
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“with expertise in development and implementation of evidencebased guidelines (1).”
BackgroundCushing, H. (1964) · Journal of Neurosurgery · doi:10.3171/jns.1964.21.4.0318 · Cited by 851 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundThe Diagnosis and Differential Diagnosis of Cushing’s Syndrome and Pseudo-Cushing’s States
Newell-Price, J., Trainer, P., Besser, M., & Grossman, A. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.5.0346 · Cited by 833
Self-citationGold, P. W., Loriaux, D. L., Roy, A., Kling, M. A., Calabrese, J. R., Kellner, C. H., Nieman, L. K., Post, R. M., Pickar, D., Gallucci, W., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198605223142101 · Cited by 766
Self-citationThe natural history of cushing's syndrome
Plotz, C. M., Knowlton, A. I., & Ragan, C. (1952) · The American Journal of Medicine · doi:10.1016/0002-9343(52)90027-2 · Cited by 763 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundTESTS OF PITUITARY-ADRENAL SUPPRESSIBILITY IN THE DIAGNOSIS OF CUSHING'S SYNDROME*
LIDDLE, G. W. (1960) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-20-12-1539 · Cited by 735
Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease
Wei, L., MacDonald, T. M., & Walker, B. R. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00007 · Cited by 730 · cited 1×
“These data are consistent with the increased cardiovascular mortality and morbidity reported in patients with iatrogenic Cushing’s syndrome secondary to the chronic use of synthetic corticosteroids (15).”
ResultMeasurements of Serum Free Cortisol in Critically Ill Patients
Hamrahian, A. H., Oseni, T. S., & Arafah, B. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa020266 · Cited by 726 · cited 1×
“are associated with decreased serum cortisol values (39, 46).”
BackgroundMorbidity and mortality in Cushing's disease: an epidemiological approach.
Etxabe, J., & Vazquez, J. A. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02486.x · Cited by 622 · cited 2×
“0-fold, compared with the general population (4, 5).”
BackgroundIncidence and Late Prognosis of Cushing’s Syndrome: A Population-Based Study1
Lindholm, J., Juul, S., Jørgensen, J. O. L., Astrup, J., Bjerre, P., Feldt-Rasmussen, U., Hagen, C., Jørgensen, J., Kosteljanetz, M., Kristensen, L. Ø., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.1.7093 · Cited by 619 · cited 6×
“Because some patients with Cushing’s disease demonstrate suppressibility to dexamethasone, use of this diagnostic criterion J Clin Endocrinol Metab, May 2008, 93(5):1526–1540 jcem.”
BackgroundInfluential
Cited by
Items 301–400 of 2,716
Vassiliadi, D. A., Ntali, G., Vicha, E., & Tsagarakis, S. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03963.x · Cited by 61
Silent, but not unseen: multimicrocystic aspect on T 2‐weighted MRI in silent corticotroph adenomas
Cazabat, L., Dupuy, M., Boulin, A., Bernier, M., Baussart, B., Foubert, L., Raffin‐Sanson, M., Caron, P. J., Bertherat, J. Y., & Gaillard, S. (2014) · Clinical Endocrinology · doi:10.1111/cen.12443 · Cited by 62
Stewart, P. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0633 · Cited by 62
Self-citationConcurrent primary aldosteronism and subclinical cortisol hypersecretion: a prospective study
Fallo, F., Bertello, C., Tizzani, D., Fassina, A., Boulkroun, S., Sonino, N., Monticone, S., Viola, A., Veglio, F., & Mulatero, P. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e32834937f3 · Cited by 61
Martins, L. C., Conceição, F. L., Muxfeldt, E. S., & Salles, G. F. (2012) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283521484 · Cited by 61
“Certain psychiatric disorders, poorly controlled diabetes mellitus and alcoholism can be associated with mild hypercortisolism and may produce laboratory results suggestive of Cushing’s syndrome, including abnormal dexamethasone suppressibility [20].”
BackgroundMethodInfluentialSmall cerebellar cortex volume in patients with active Cushing’s syndrome
Santos, A., Resmini, E., Crespo, I., Pires, P., Vives-Gilabert, Y., Granell, E., Valassi, E., Gómez-Anson, B., Martínez-Momblán, M. A., Mataró, M., et al. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0371 · Cited by 60
Olsen, H., Nordenström, E., Bergenfelz, A., Nyman, U., Valdemarsson, S., & Palmqvist, E. (2012) · Endocrine · doi:10.1007/s12020-012-9622-2 · Cited by 60
Use of late-night salivary cortisol to monitor response to medical treatment in Cushing's disease
Newell-Price, J., Pivonello, R., Tabarin, A., Fleseriu, M., Witek, P., Gadelha, M. R., Petersenn, S., Tauchmanova, L., Ravichandran, S., Gupta, P., et al. (2020) · European Journal of Endocrinology · doi:10.1530/eje-19-0695 · Cited by 60
Self-citationPaediatric Pituitary Adenomas: A Decade of Change
Guaraldi, F., Storr, H. L., Ghizzoni, L., Ghigo, E., & Savage, M. O. (2014) · Hormone Research in Paediatrics · doi:10.1159/000357673 · Cited by 58
Self-citationDebono, M., Chadarevian, R., Eastell, R., Ross, R. J., & Newell-Price, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060984 · Cited by 60
“8 ug/dL) on 1 mg over-night dexamethasone suppression and 2 mg/day 48 hour low-dose dexamethasone suppression testing [18].”
BackgroundInfluentialSelf-citationPofi, R., & Tomlinson, J. (2019) · Obstetric Medicine · doi:10.1177/1753495x19847832 · Cited by 77
“Thus, unless levels are more than three times higher than the upper limit of normal values, this cannot be considered a reliable marker of CS after the first trimester.(42) However, late night salivary cortisol may be more helpful, especially during the first and the second trimesters.”
Pituitary Adenomas: From Diagnosis to Therapeutics
Banskota, S., & Adamson, D. C. (2021) · Biomedicines · doi:10.3390/biomedicines9050494 · Cited by 85
“There are three screening tests to confirm hypercortisolism: (i) 24-h urinary free cortisol; (ii) low-dose dexamethasone suppression test; and (iii) late-night salivary cortisol [97,100].”
BackgroundMethodInfluentialThe Burden of Hormonal Disorders: A Worldwide Overview With a Particular Look in Italy
Crafa, A., Calogero, A. E., Cannarella, R., Mongioì, L. M., Condorelli, R. A., Greco, E. A., Aversa, A., & Vignera, S. L. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.694325 · Cited by 79
“Addison’s disease Hypotension, hypoglycemia, and electrolyte imbalances (particularly in forms also associated with mineralocorticoid deficiency) (6) Cushing’s syndrome Hypertension, diabetes mellitus, obesity, osteoporosis (7)”
BackgroundCortisol Immunosensors: A Literature Review
Karachaliou, C., Koukouvinos, G., Goustouridis, D., Raptis, I., Kakabakos, S. E., Petrou, P. S., & Livaniou, E. (2023) · Biosensors · doi:10.3390/bios13020285 · Cited by 76
“Measurement of 24 h UFC, which is not affected by diurnal variation, is considered to reliably reflect tissue exposure to free cortisol over a day, and has therefore been used as a well-established screening test for the diagnosis of Cushing’s syndrome, as already mentioned [1,7,8].”
MethodPeris-Pastor, G., Azorín, C., Grau, J., Benedé, J. L., & Chisvert, A. (2023) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2023.117434 · Cited by 68
Fagour, C., Bardet, S., Rohmer, V., Arimone, Y., Lecomte, P., Valli, N., & Tabarin, A. (2009) · European Journal of Endocrinology · doi:10.1530/eje-08-0299 · Cited by 59
Kassotis, C. D., & Stapleton, H. M. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00039 · Cited by 65
“Cushing’s syndrome (excess cortisol production) is associated with increased weight gain, hypertension, type 2 diabetes, and fatty tissue deposits (143, 144), suggesting a pro-adipogenic effect of glucocorticoids in humans as well.”
BackgroundJohnston, P. C., Lansang, M. C., Chatterjee, S., & Kennedy, L. (2015) · Endocrine · doi:10.1007/s12020-014-0409-5 · Cited by 58
“Cushing syndrome is typically demonstrated by elevations in serum or urine cortisol, sequential midnight salivary cortisol as well as dexamethasone suppression testing [65, 66].”
Diagnostic tests for Cushing’s syndrome differ from published guidelines: data from ERCUSYN
Valassi, E., Franz, H., Brue, T., Feelders, R. A., Netea-Maier, R., Tsagarakis, S., Webb, S. M., Yaneva, M., Reincke, M., Droste, M., et al. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0967 · Cited by 58
Varlamov, E. V., Langlois, F., Vila, G., & Fleseriu, M. (2021) · European Journal of Endocrinology · doi:10.1530/eje-20-1309 · Cited by 58
The diagnosis and management of Cushing's syndrome in pregnancy
Hamblin, R., Coulden, A., Fountas, A., & Karavitaki, N. (2022) · Journal of Neuroendocrinology · doi:10.1111/jne.13118 · Cited by 63
“Tumour detection can therefore prove difficult; 40% of pituitary microadenomas are not detected by pituitary MRI and, when detected, they may be incidental, clinically irrelevant findings.(8,56)”
BackgroundInfluentialMorelli, V., Frigerio, S., Aresta, C., Passeri, E., Pugliese, F., Copetti, M., Barbieri, A. M., Fustinoni, S., Polledri, E., Corbetta, S., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.898084 · Cited by 69
Bou Khalil, R., Baudry, C., Guignat, L., Carrasco, C., Guibourdenche, J., Gaillard, S., Bertagna, X., & Bertherat, J. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0424 · Cited by 58
Burman, P., Engström, B. E., Ekman, B., Karlsson, F. A., Schwarcz, E., & Wahlberg, J. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0807 · Cited by 59
Palmieri, S., Morelli, V, Polledri, E., Fustinoni, S., Mercadante, R., Olgiati, L., Eller Vainicher, C., Cairoli, E., Zhukouskaya, V. V., Beck-Peccoz, P., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-12-0803 · Cited by 57
Pros and cons of screening for occult Cushing syndrome
Tabarin, A., & Perez, P. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.51 · Cited by 57
Espiard, S., Vantyghem, M., Assié, G., Cardot-Bauters, C., Raverot, G., Brücker-Davis, F., Archambeaud-Mouveroux, F., Lefèbvre, H., Nunes, M. L., Tabarin, A., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa002 · Cited by 65
Is urinary free cortisol of value in the diagnosis of Cushingʼs syndrome?
Alexandraki, K. I., & Grossman, A. B. (2011) · Current Opinion in Endocrinology, Diabetes and Obesity · doi:10.1097/med.0b013e3283487193 · Cited by 57
MANAGEMENT OF ENDOCRINE DISEASE: Management of pregnant patients with Cushing's syndrome
Bronstein, M. D., Machado, M. C., & Fragoso, M. C. B. V. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-1130 · Cited by 60
MANAGEMENT OF ENDOCRINE DISEASE: Paediatric Cushing's disease
Storr, H. L., & Savage, M. O. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0013 · Cited by 62
Self-citationReoperative endoscopic endonasal surgery for residual or recurrent pituitary adenomas
Negm, H. M., Al-Mahfoudh, R., Pai, M., Singh, H., Cohen-Cohen, S., Dhandapani, S., Anand, V. K., & Schwartz, T. H. (2016) · Journal of neurosurgery · doi:10.3171/2016.8.jns152709 · Cited by 61
Pituitary Physiology and Diagnostic Evaluation
Melmed, S. K., Kleinberg, D. L., & Ho, K. K. Y. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00008-0 · Cited by 64
How We Manage Bone Marrow Edema—An Interdisciplinary Approach
Baumbach, S. F., Pfahler, V., Pozza, S. B., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020551 · Cited by 57
“In the case of clinical suspicion, a 1 mg overnight dexamethasone suppression test (or late night salivary cortisol or 24 h urin free cortisol) is recommended [81].”
BackgroundLiu, Y., Wu, B., Tanyi, E. K., Yeasmin, S., & Cheng, L.-J. “. (2020) · Langmuir · doi:10.1021/acs.langmuir.0c00513 · Cited by 56
Automated 24-hours sampling of subcutaneous tissue free cortisol in humans
Bhake, R. C., Leendertz, J. A., Linthorst, A. C. E., & Lightman, S. L. (2013) · Journal of Medical Engineering & Technology · doi:10.3109/03091902.2013.773096 · Cited by 56
“In routine clinical practice, the pattern of HPA activity is often inferred from two, or a few isolated time-point measurements in the blood or saliva [11] while, often, pharmacological manipulation has to be employed to interrogate the HPA axis [11,12].”
BackgroundAlopecia and the metabolic syndrome
Lie, C. J. L., Liew, C. F., & Oon, H. H. B. (2017) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2017.09.009 · Cited by 64
Updates in adrenal steroidogenesis inhibitors for Cushing’s syndrome – A practical guide
Varlamov, E. V., Han, A. J., & Fleseriu, M. (2021) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2021.101490 · Cited by 60
Clinical practice guideline for the management of hypertension in China
Chinese Society of Cardiology, C. M. A., Hypertension Committee of Cross-Straits Medicine Exchange Association, & Cardiovascular Disease Prevention and Rehabilitation Committee, C. A. O. R. M. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003431 · Cited by 68
Management of Adrenal Tumors in Pregnancy
Eschler, D. C., Kogekar, N., & Pessah‐Pollack, R. (2015) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2015.02.006 · Cited by 57
Belaya, Z. E., Iljin, A. V., Mel'nichenko, G. A., Rozhinskaya, L. Y., Dragunova, N. V., Dzeranova, L. K., Бутрова, С. А., Troshina, E. A., & Dedov, I. I. (2012) · Endocrine · doi:10.1007/s12020-012-9658-3 · Cited by 57
DHEAS for the prediction of subclinical Cushing’s syndrome: perplexing or advantageous?
Yener, S., Yilmaz, H., Demir, T., Seçil, M., & Çömlekçi, A. (2014) · Endocrine · doi:10.1007/s12020-014-0387-7 · Cited by 60
Ceccato, F., Antonelli, G., Barbot, M., Zilio, M., Mazzai, L., Gatti, R., Zaninotto, M., Mantero, F., Boscaro, M., Plebani, M., et al. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0061 · Cited by 56
Psychometric performance of the CushingQoL questionnaire in conditions of real clinical practice
Vives, A. S., Resmini, E., Martínez-Momblán, M.-A., Crespo, I., Valassi, E., Roset, M., Badia, X. C., & Webb, S. M. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0325 · Cited by 57
Fredman, R., & Tenenhaus, M. (2012) · Burns · doi:10.1016/j.burns.2012.09.020 · Cited by 57
“[14] Nieman LK, Biller BMK, Findling JW, Newell-Price J, Savage MO, Stewart PM, et al.”
BackgroundCurrent management of Cushing's disease
Tritos, N. A., & Biller, B. M. K. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12975 · Cited by 60
Self-citationRossitto, G., Maiolino, G., Lerco, S., Ceolotto, G., Blackburn, G. J., Mary, S., Antonelli, G., Berton, C., Bisogni, V., Cesari, M., et al. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa205 · Cited by 64
León-Justel, A., Madrazo-Atutxa, A., Alvarez-Rios, A. I., Infantes-Fontán, R., Garcia-Arnés, J. A., Lillo-Muñoz, J. A., Aulinas, A., Urgell-Rull, E., Boronat, M., Sánchez-de-Abajo, A., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1673 · Cited by 52
Savas, M., Vinkers, C. H., Rosmalen, J. G. M., Hartman, C. A., Wester, V. L., van den Akker, E. L. T., Iyer, A. M., McEwen, B. S., & van Rossum, E. F. C. (2020) · Neuroendocrinology · doi:10.1159/000501617 · Cited by 55
Salivary Cortisol Concentrations in Healthy Dogs and Dogs with Hypercortisolism
Wenger-Riggenbach, B., Boretti, F. S., Quante, S., Schellenberg, S., Reusch, C. E., & Sieber-Ruckstuhl, N. S. (2010) · Journal of Veterinary Internal Medicine · doi:10.1111/j.1939-1676.2010.0494.x · Cited by 54
Debono, M., Prema, A., Hughes, T. J. B., Bull, M., Ross, R. J., & Newell-Price, J. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4276 · Cited by 54
Self-citationMifepristone for Management of Cushing's Syndrome
Morgan, F. H., & Laufgraben, M. J. (2013) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1202 · Cited by 54
“The excess cortisol seen in Cushing’s syndrome results in hypertension, hyperglycemia, obesity, and a myriad of other problems (Table 1).(5) These complications lead to significant morbidity related to illness and twice the mortality rate in patients with Cushing’s syndrome compared to the general population.”
BackgroundRaff, H., & Phillips, J. M. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00186 · Cited by 53
Sereg, M., Tőke, J., Patócs, A., Varga, I., Igaz, P., Szücs, N., Horányi, J., Pusztai, P., Czirják, S., Gláz, E., et al. (2011) · Steroids · doi:10.1016/j.steroids.2010.08.007 · Cited by 53
“Many years after the initial reports of salivary cortisol deterination [1] midnight salivary cortisol, along with low dose examethasone test (LDDST) and urinary free cortisol (UFC) meaurement [2], has become a first-line laboratory method in the iagnosis of Cushing’s syndrome (CS).”
MethodTrementino, L., Appolloni, G., Concettoni, C., Cardinaletti, M., Boscaro, M., & Arnaldi, G. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-0722 · Cited by 53
Paediatric Cushing’s disease: Epidemiology, pathogenesis, clinical management and outcome
Ferrigno, R., Hasenmajer, V., Caiulo, S., Minnetti, M., Mazzotta, P., Storr, H. L., Isidori, A. M., Grossman, A. B., Martino, M. C. D., & Savage, M. O. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09626-4 · Cited by 64
“In CD, the ACTH secreting pituitary adenoma is reported to give an exaggerated response to CRH resulting in an elevated cortisol response [66, 67].”
BackgroundSelf-citationGlucose and lipid metabolism abnormalities in C ushing's syndrome
Salehidoost, R., & Korbonits, M. (2022) · Journal of Neuroendocrinology · doi:10.1111/jne.13143 · Cited by 65
“tality and morbidity compared to the healthy population because of the adverse effects of hypercortisolism.(1,5) Prolonged hypercortisolism has adverse systemic effects leading to metabolic, cardiovascular, immunological, reproductive, neuropsychiatric and musculoskeletal disorders.”
BackgroundRonchi, C. L., Sbiera, S., Volante, M., Steinhauer, S., Scott-Wild, V., Altieri, B., Kroiß, M., Bala, M., Papotti, M. G., Deutschbein, T., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105855 · Cited by 55
“Malignancy and hormonal hypersecretion were defined according to established clinical, biochemical, and morphological criteria [19].”
BackgroundAulinas, A., Ramírez, M., Barahona, M. J., Valassi, E., Resmini, E., Mato, E., Vives, A. S., Crespo, I., Bell, O. L., Surrallés, J., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120185 · Cited by 55
“Cushing’s syndrome (CS) due to chronic exposure to endogenous hypercortisolism may be caused by a pituitary adenoma, an adrenocortical tumor or ectopic adrenocorticotropic hormone (ACTH) or corticotropin-releasing hormone (CRH) production [1].”
BackgroundMebendazole Monotherapy and Long-Term Disease Control in Metastatic Adrenocortical Carcinoma
Dobrosotskaya, I. Y., Hammer, G. D., Schteingart, D. E., Maturen, K. E., & Worden, F. P. (2011) · Endocrine Practice · doi:10.4158/ep10390.cr · Cited by 53
Mini-review: pheochromocytomas causing the ectopic ACTH syndrome
Ballav, C., Naziat, A., Mihai, R., Karavitaki, N., Ansorge, O., & Grossman, A. B. (2012) · Endocrine · doi:10.1007/s12020-012-9646-7 · Cited by 59
Alzahrani, A. S., Farhat, R., Alarifi, A., Alkahtani, N. S., Kanaan, I., & Abouzied, M. (2009) · Pituitary · doi:10.1007/s11102-009-0180-4 · Cited by 53
“The diagnostic work up of Cushing’s syndrome can be challenging at many stages including the exclusion of pseudo Cushing’s syndrome, defining the cause of ACTHdependent Cushing’s syndrome and the localization of the source of ACTH, whether it is caused by pituitary adenoma or by an ectopic ACTH-secreting tumor [1, 2].”
BackgroundWannachalee, T., Turcu, A. F., Bancos, I., Habra, M. A., Avram, A. M., Chuang, H. H., Waguespack, S. G., & Auchus, R. J. (2019) · Clinical Endocrinology · doi:10.1111/cen.14008 · Cited by 53
Braun, L. T., Vogel, F., Zopp, S., Marchant Seiter, T., Rubinstein, G., Berr, C. M., Künzel, H., Beuschlein, F., & Reincke, M. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac379 · Cited by 52
“Standard biochemical screening was performed according to guidelines (26, 31), including a sample of 24-hour urine cortisol, late-night salivary cortisol, and 1-mg low-dose dexamethasone suppression test in all patients.”
Sistema endocrino y corazón: una revisión
Rhee, S. S., & Pearce, E. N. (2011) · Revista Española de Cardiología · doi:10.1016/j.recesp.2010.10.015 · Cited by 56
Adrenal disorders in pregnancy
Monticone, S., Auchus, R. J., & Rainey, W. E. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.155 · Cited by 58
Hawley, J. M., & Keevil, B. G. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.05.014 · Cited by 56
Nonfunctioning adrenal incidentaloma: A novel predictive factor for metabolic syndrome
Cavalari, E. M. R., de Paula, M. P., Arruda, M., Carraro, N., Martins, A., de Souza, K., Coelho, M. C. A., de Morais, N. A. D. O. E. S., Moraes, A. B., & Neto, L. V. (2018) · Clinical Endocrinology · doi:10.1111/cen.13822 · Cited by 58
Walia, R., Gupta, R., Bhansali, A., Pivonello, R., Kumar, R., Singh, H., Ahuja, C., Chhabra, R., Singh, A., Dhandapani, S., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa755 · Cited by 53
The role of corticosteroid-binding globulin in the evaluation of adrenal insufficiency
Verbeeten, K. C., & Ahmet, A. H. (2018) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2017-0270 · Cited by 51
“If a reagent is used, then it must be added in sufficient quantities to allow for high-CBG states, such as pregnancy or oral contraceptive use, or cortisol levels will be underestimated [21, 23].”
BackgroundInfluentialDifferentiating Polycystic Ovary Syndrome from Adrenal Disorders
Yeşiladalı, M., Yazici, M. G. K., Attar, E., & Keleştimur, F. (2022) · Diagnostics · doi:10.3390/diagnostics12092045 · Cited by 69
“An abdominal computed tomography (CT) or magnetic resonance imaging (MRI) scan should be performed if suspicion is high.”
MethodErickson, D., Singh, R. J., Sathananthan, A., Vella, A., & Bryant, S. C. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04239.x · Cited by 51
Castinetti, F., Martinie, M., Morange, I., Dufour, H., Sturm, N., Passagia, J.-G., Conte-Devolx, B., Chabre, O., & Brue, T. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2234 · Cited by 51
“The diagnosis of CD was based on the combination of clinical features of hypercortisolism and biochemical assessment according to recommended guidelines (28).”
MethodCushing's disease: a multidisciplinary overview of the clinical features, diagnosis, and treatment.
Buliman, A., Tătăranu, L. G., Păun, D. L., Mirică, A., & Dumitrache, C. (2016) · PubMed Central · Cited by 73
Usefulness of 68Ga-Pentixafor PET/CT on Diagnosis and Management of Cushing Syndrome
Ding, J., Tong, A., Hacker, M., Feng, M., Huo, L., & Li, X. (2022) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000004244 · Cited by 55
Tirabassi, G., Papa, R., Faloia, E., Boscaro, M., & Arnaldi, G. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04096.x · Cited by 50
Leistner, S., Klotsche, J., Dimopoulou, C., Athanasoulia, A. P., Roemmler-Zehrer, J., Pieper, L., Schopohl, J., Wïttchen, H., Stalla, G. K., Fulda, S., et al. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-0941 · Cited by 51
Doğanşen, S. Ç., Yalın, G. Y., Tanrıkulu, S., Tekin, S., Nizam, N., Bılgıç, B., Sencer, S., & Yarman, S. (2018) · Pituitary · doi:10.1007/s11102-018-0877-3 · Cited by 57
Perlman, J. E., Johnston, P. C., Hui, F., Mulligan, G., Weil, R. J., Recinos, P. F., Yogi-Morren, D., Salvatori, R., Mukherjee, D., Gallia, G., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab012 · Cited by 50
The Adrenal Cortex and its Disorders
Miller, W. L. (2009) · Brook's Clinical Pediatric Endocrinology · doi:10.1002/9781444316728.ch13 · Cited by 50
Fallo, F., Di Dalmazi, G., Beuschlein, F., Biermasz, N. R., Castinetti, F., Elenkova, A., Fassnacht, M., Isidori, A. M., Kastelan, D., Korbonits, M., et al. (2022) · Journal of Hypertension · doi:10.1097/hjh.0000000000003252 · Cited by 49
“Three main hormonal tests are currently used for biochemical screening of Cushing’s syndrome in patients with a suspicious clinical picture (after excluding glucocorticoid intake): overnight 1mg dexamethasone suppression test (1mg DST), 24-h urinary free cortisol (24-h UFC), and late-night salivary or serum cortisol […”
BackgroundMethodInfluentialSelf-citationPrevalence of Functioning Adrenal Incidentalomas: A Systematic Review and Meta-analysis
Sconfienza, E., Tetti, M., Forestiero, V., Veglio, F., Mulatero, P., & Monticone, S. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad044 · Cited by 61
Bone density and microarchitecture in endogenous hypercortisolism
dos Santos, C. V., Vieira Neto, L., Madeira, M., Alves Coelho, M. C., de Mendonça, L. M. C., Paranhos‐Neto, F. D. P., Lima, I. C. B., Gadelha, M. R., & Farias, M. L. F. (2015) · Clinical Endocrinology · doi:10.1111/cen.12812 · Cited by 49
Evaluation of the diagnostic criteria for Cushing’s disease in Japan [Review]
Kageyama, K., Oki, Y., Sakihara, S., Nigawara, T., Terui, K., & Suda, T. (2013) · Endocrine Journal · doi:10.1507/endocrj.ej12-0299 · Cited by 49
GENETICS IN ENDOCRINOLOGY: Glucocorticoid resistance syndrome
Vitellius, G., & Lombès, M. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0811 · Cited by 54
Briassoulis, G., Damjanovic, S., Xekouki, P., Lefebvre, H., & Stratakis, C. A. (2011) · Endocrine Practice · doi:10.4158/ep11061.ra · Cited by 48
“Despite the rarity of mutations, GR insensitivity is so widespread in ACTH-producing tumors that we take advantage of this phenomenon in diagnostic testing for CS by using various dexamethasone doses (and administration regimens) to distinguish among normal HPA axis function, pituitary and ACTH-dependent causes (Cushi…”
BackgroundAdrenal incidentalomas and subclinical Cushing's syndrome: diagnosis and treatment.
Mazzuco, T. L., Bourdeau, I., & Lacroix, A. (2009) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e32832b7043 · Cited by 48
Bekő, G., Varga, I., Gláz, E., Sereg, M., Feldman, K., Tóth, M., Rácz, K., & Patócs, A. (2009) · Clinica Chimica Acta · doi:10.1016/j.cca.2009.11.033 · Cited by 48
Zerikly, R. K., Amiri, L., Faiman, C., Gupta, M., Singh, R. J., Nutter, B., Kennedy, L., Hatipoglu, B., Weil, R. J., & Hamrahian, A. H. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2458 · Cited by 48
Daimon, M., KAMBA, A., Murakami, H., Takahashi, K., Otaka, H., Makita, K., Yanagimachi, M., Terui, K., Kageyama, K., Nigawara, T., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3568 · Cited by 54
Cushing's syndrome: a practical approach to diagnosis and differential diagnoses
Pappachan, J. M., Hariman, C., Edavalath, M., Waldron, J., & Hanna, F. W. (2017) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2016-203933 · Cited by 48
“Newer IAs are capable of detecting low cortisol levels at small volumes of saliva used for LNSC. Similar to the measurements of UFC and serum cortisol, chromatographic methods using mass spectrometry may give better diagnostic yield in LNSC. 38 39 However, spectroscopic methods require higher volumes of saliva (100 –…”
BackgroundMethodInfluentialPotential utility of FLAIR in MRI-negative Cushing’s disease
Chatain, G. P., Patronas, N., Smirniotopoulos, J. G., Piazza, M., Benzo, S., Ray-Chaudhury, A., Sharma, S., Lodish, M., Nieman, L., Stratakis, C. A., et al. (2018) · Journal of Neurosurgery · doi:10.3171/2017.4.jns17234 · Cited by 48
Self-citationHaddad, R. A., Giacherio, D. A., & Barkan, A. L. (2019) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-019-0086-7 · Cited by 56
Prodam, F., Ricotti, R., Agarla, V., Parlamento, S., Genoni, G., Balossini, C., Walker, G. E., Aimaretti, G., Bona, G., & Bellone, S. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-44 · Cited by 47
“Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM: The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline.”
MethodDeep-Learning Approach to Automatic Identification of Facial Anomalies in Endocrine Disorders
Ren, W., Jiang, C., Gao, J., Xu, P., Zhang, D., Sun, Z., Liu, X., Deng, K., Bao, X., Sun, G., et al. (2019) · Neuroendocrinology · doi:10.1159/000502211 · Cited by 51
Ceccato, F., Barbot, M., Mondin, A., Boscaro, M., Fleseriu, M., & Scaroni, C. M. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac686 · Cited by 51
Korbonits, M., Blair, J., Bogusławska, A., Ayuk, J., Davies, J. H., Druce, M. R., Evanson, J., Flanagan, D., Glynn, N., Higham, C., et al. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00949-7 · Cited by 71
“The algorithms for testing consist initially of confirmation or exclusion of the diagnosis of hypercortisolaemia and then investigations to determine its aetiology 81 .”
InfluentialMulligan, G. B., Eray, E., Faiman, C., Gupta, M. K., Pineyro, M. M., Makdissi, A., Suh, J. H., Masaryk, T. J., Prayson, R. A., Weil, R. J., et al. (2010) · Endocrine Practice · doi:10.4158/ep10067.or · Cited by 51
Carrozza, C., Corsello, S. M., Paragliola, R. M., Ingraudo, F., Palumbo, S., Locantore, P., Sferrazza, A., Pontecorvi, A., & Zuppi, C. (2010) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1258/acb.2010.010020 · Cited by 47
Six controversial issues on subclinical Cushing’s syndrome
on behalf of the ABC Group, Chiodini, I., Albani, A., Ambrogio, A. G., Campo, M., Martino, M. C. D., Marcelli, G., Morelli, V., Zampetti, B., Colao, A. A. L., et al. (2016) · Endocrine · doi:10.1007/s12020-016-1017-3 · Cited by 53
Acharya, R., Dhir, M., Bandi, R., Yip, L., & Challinor, S. M. (2018) · World Journal of Surgery · doi:10.1007/s00268-018-4788-2 · Cited by 48
Metadata
- Authors
- Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M.
- Affiliations
- National Institutes of Health (US)
- Massachusetts General Hospital (US)
- Medical College of Wisconsin (US)
- University of Sheffield (GB)
- Queen Mary University of London (GB)
- University of Birmingham (GB)
- Mayo Clinic (V.M.M.), Rochester, Minnesota 55905
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2008-05-01
- Volume
- 93
- Issue
- 5
- Pages
- 1526-1540
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC2386281
- OpenAlex
- W1990995386
- Cited by
- 2,718
- References
- 140
- Citations by year
- 2026: 159 · 2025: 173 · 2024: 173 · 2023: 148 · 2022: 212 · 2021: 199 · 2020: 195 · 2019: 165 · 2018: 150 · 2017: 148 · 2016: 158 · 2015: 156 · 2014: 134 · 2013: 139 · 2012: 114
- FWCI
- 70.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- European Society of Endocrinology
- National Institutes of Health
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (Z01HD008833)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- Cushing's syndrome, diagnosis, hypercortisolism, adrenal incidentaloma, dexamethasone suppression test, late-night salivary cortisol, urine cortisol
- MeSH terms
- Cushing Syndrome, Dexamethasone, Humans, Hydrocortisone, Saliva, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.